All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-003977-10 | A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Primar... | 2008-06-05 | due-trials |
| Reported results | 2004-004107-37 | A Randomized Trial Comparing Preservation of Function Status After Either MedPulser® Electroporation with Intraumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary ... | 2008-06-05 | due-trials |
| Reported results | 2012-001334-33 | PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA®-5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR CIN... | 2016-01-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002761-63 | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA¿ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-... | 2021-04-06 | bad-data |
| Exempt Terminated | 2018-000309-21 | An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Ensayo abierto ... | 2019-07-16 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2018-004114-17 | REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 a... | 2022-09-15 | bad-data |